The inhibitory effect of gallamine on muscarinic receptors.

British Journal of Pharmacology
A L Clark, F Mitchelson


1 The inhibitory effect of gallamine (1.1 muM-1.1 mM) on negative inotropic responses to acetylcholine (ACh) or carbachol (CCh) was investigated in isolated electrically stimulated atria of the guinea-pig. Gallamine caused parallel rightward shifts of the dose-response curves to the agonists, with no depression of the maximal response. 2 Gallamine (0.11 - 1.1 mM) produced a greater degree of antagnism towards CCh than towards ACh. With either agonist, the degree of antagonism produced by gallamine in high concentrations was less than that expected for a competitive antagonist.. 3 Similar findings were made when either negative inotropic or chronotropic responses were recorded in spontaneously beating guinea-pig atria. The inhibitory effect of gallamine against the negative inotropic response to cholinomimetics in electrically stimulated atria was not altered either in the presence of propranol (17 muM) or in atria obtained from guinea-pigs pretreated with diisopropylphosphorofluoridate (DEP) 12.5 mumol/kg, in divided doses over 3 days). 4 When ACh was used as the agonist, combination of gallamine with atropine (0.05-0.4 muM) produced dose-ratios which were less than expected for combination of two competitive antagonists. The s...Continue Reading


May 1, 1975·European Journal of Pharmacology·J Madden, F Mitchelson
Jan 1, 1970·Naunyn-Schmiedebergs Archiv Für Pharmakologie·K Löffelholz
May 24, 1969·Nature·R P Stephenson, B L Ginsborg
Jun 1, 1974·British Journal of Pharmacology·B L Gingsborg, R P Stephenson
Jun 9, 1972·European Journal of Biochemistry·C G ButchardA V Xavier
Jun 1, 1970·Proceedings of the Society for Experimental Biology and Medicine·D J MiletichT A Strike
Jan 1, 1970·European Journal of Pharmacology·D Kuhnen-Clausen
Nov 1, 1970·Canadian Anaesthetists' Society Journal·F J Rathbun, J T Hamilton
Mar 1, 1954·British Journal of Pharmacology and Chemotherapy·A TODRICK
Mar 1, 1959·British Journal of Pharmacology and Chemotherapy·O ARUNLAKSHANA, H O SCHILD
Aug 24, 1965·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·W D PATON, H P RANG
Oct 1, 1951·Annals of the New York Academy of Sciences·W F RIKER, W C WESCOE
Aug 1, 1965·British Journal of Pharmacology and Chemotherapy·A S Burgen

❮ Previous
Next ❯


Jul 1, 1990·Medicinal Research Reviews·C Melchiorre
Apr 1, 1987·Naunyn-Schmiedeberg's Archives of Pharmacology·A D Fryer, J Maclagan
Jun 20, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Klaus Mohr, Christian Tränkle
Sep 28, 2007·Pflügers Archiv : European journal of physiology·Oleg E Osadchii
Jul 5, 1991·Biochemical Pharmacology·N H Lee, E E el-Fakahany
Oct 1, 1978·European Journal of Pharmacology·C K Li, F Mitchelson
May 7, 1982·European Journal of Pharmacology·E Leung, F Mitchelson
Jul 9, 1982·European Journal of Pharmacology·V P CherepanovaS F Torf
Oct 26, 1988·European Journal of Pharmacology·S B FreedmanE A Harley
Apr 25, 1989·European Journal of Pharmacology·N R Newberry, M J Gilbert
Aug 3, 1989·European Journal of Pharmacology·A D MichelR L Whiting
Jul 3, 1990·European Journal of Pharmacology·A D MichelR L Whiting
Jan 3, 1991·European Journal of Pharmacology·H DoodsN Mayer
Jun 3, 1996·European Journal of Pharmacology·A Maass, K Mohr
Jan 1, 1988·Pharmacology & Therapeutics·F Mitchelson
Jan 1, 1984·Nihon rinsho. Japanese journal of clinical medicine·S KishimotoA Miyoshi
May 1, 1988·Trends in Pharmacological Sciences·G Tomlinson
Jun 1, 1988·Trends in Pharmacological Sciences·C Melchiorre
Mar 23, 2004·European Journal of Pharmacology·Adèle ThomasRoger G Pertwee
Mar 5, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anders A Jensen, Tracy A Spalding
Apr 6, 2001·European Journal of Pharmacology·A LanzafameF Mitchelson
Nov 28, 1996·European Journal of Pharmacology·A LanzafameF Mitchelson
Mar 18, 2000·Pharmacology & Therapeutics·K N Bradley

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.